IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.911
AS - Asia 5.771
EU - Europa 2.745
SA - Sud America 1.286
Continente sconosciuto - Info sul continente non disponibili 329
AF - Africa 139
OC - Oceania 23
Totale 20.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.447
SG - Singapore 2.619
IT - Italia 1.315
CN - Cina 1.284
BR - Brasile 974
IN - India 583
VN - Vietnam 573
GB - Regno Unito 341
SE - Svezia 332
CA - Canada 292
DE - Germania 263
HK - Hong Kong 155
BD - Bangladesh 114
AR - Argentina 109
FI - Finlandia 96
ID - Indonesia 81
NL - Olanda 68
MX - Messico 61
EC - Ecuador 53
RU - Federazione Russa 52
IQ - Iraq 49
UA - Ucraina 44
ZA - Sudafrica 43
JP - Giappone 42
CO - Colombia 41
PK - Pakistan 40
FR - Francia 38
ES - Italia 34
JO - Giordania 34
RO - Romania 31
PY - Paraguay 30
SA - Arabia Saudita 29
TR - Turchia 26
VE - Venezuela 26
CL - Cile 23
CR - Costa Rica 23
PL - Polonia 23
EG - Egitto 22
EU - Europa 22
IR - Iran 19
AU - Australia 17
CZ - Repubblica Ceca 16
GT - Guatemala 16
PE - Perù 16
AT - Austria 15
HN - Honduras 15
KE - Kenya 14
MA - Marocco 14
MY - Malesia 13
AE - Emirati Arabi Uniti 12
LT - Lituania 12
IE - Irlanda 11
IL - Israele 11
KR - Corea 11
PR - Porto Rico 11
NG - Nigeria 10
PT - Portogallo 10
TN - Tunisia 10
UZ - Uzbekistan 10
EE - Estonia 9
JM - Giamaica 9
UY - Uruguay 9
PH - Filippine 8
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
ET - Etiopia 7
LB - Libano 7
NI - Nicaragua 7
BG - Bulgaria 6
SV - El Salvador 6
DO - Repubblica Dominicana 5
KZ - Kazakistan 5
NP - Nepal 5
SC - Seychelles 5
TW - Taiwan 5
AL - Albania 4
CH - Svizzera 4
CU - Cuba 4
CW - ???statistics.table.value.countryCode.CW??? 4
CY - Cipro 4
HR - Croazia 4
NZ - Nuova Zelanda 4
SN - Senegal 4
TH - Thailandia 4
BB - Barbados 3
BO - Bolivia 3
DZ - Algeria 3
GE - Georgia 3
LK - Sri Lanka 3
PA - Panama 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BN - Brunei Darussalam 2
GR - Grecia 2
GY - Guiana 2
HU - Ungheria 2
KG - Kirghizistan 2
KI - Kiribati 2
Totale 19.878
Salva come PNG Salva come JPEG
Città #
San Jose 1.954
Ashburn 911
Chandler 826
Singapore 808
Santa Clara 500
Council Bluffs 415
Hefei 399
Bengaluru 396
Dallas 395
Milan 376
Princeton 355
Lawrence 351
Chicago 257
Ho Chi Minh City 221
London 221
Beijing 216
Munich 198
Wilmington 190
Ottawa 160
Hong Kong 141
Des Moines 118
Catanzaro 110
Hanoi 108
Los Angeles 102
New York 96
São Paulo 88
Phoenix 77
Turku 66
Rome 64
Boardman 62
Shanghai 48
Naples 43
Montreal 35
Pune 35
Rio de Janeiro 35
Norwalk 34
Tokyo 32
Brooklyn 31
Guangzhou 31
San Francisco 30
Haiphong 29
Helsinki 29
Da Nang 28
Redmond 28
The Dalles 27
Atlanta 26
Amman 25
Chennai 24
Warsaw 23
Redwood City 22
Toronto 22
Manchester 21
Seattle 21
San José 20
Thái Bình 20
Boston 19
Curitiba 19
Dhaka 19
Mexico City 19
Orem 19
Baghdad 18
Buffalo 18
Denver 18
Jeddah 18
Parma 18
Columbus 17
San Nicola Manfredi 16
Shenzhen 16
Stockholm 16
Amsterdam 15
Biên Hòa 15
Guayaquil 15
Johannesburg 15
Porto Alegre 15
Horia 14
Salvador 14
Belo Horizonte 13
Guatemala City 13
Palermo 13
Quito 13
Reggio Calabria 13
Augusta 12
Aversa 12
Cape Town 12
Carbonia 12
Cosenza 12
Frankfurt am Main 12
Nairobi 12
Spezzano della Sila 12
Washington 12
Campinas 11
Charlotte 11
Delhi 11
Hanover 11
Jakarta 11
Madrid 11
Mountain View 11
Olomouc 11
Recife 11
Salt Lake City 11
Totale 11.536
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 507
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 154
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 129
miR-22 suppresses DNA ligase III addiction in multiple myeloma 116
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 109
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 106
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 101
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 99
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 98
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 97
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 91
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 90
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 90
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 88
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 87
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 86
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 86
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 84
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 84
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 84
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 84
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 83
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 82
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 82
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 82
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 81
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 81
Mir-34: a new weapon against cancer? 80
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 80
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 80
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 80
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 79
Fetal ontogeny and tumor expression of the early thymic antigen UN1 79
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 79
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 78
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 77
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 77
POLYAMINE UPTAKE BY HUMAN COLON-CARCINOMA CELL-LINE CACO-2 77
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 77
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 76
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 76
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 76
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 75
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 75
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 74
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 74
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 74
Anti-myeloma activity of miR-125 mimics 74
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 74
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 73
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 73
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 71
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 71
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 70
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 70
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 70
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 69
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 69
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 68
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 68
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 68
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 67
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 67
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study 67
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 67
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 66
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 66
Mir-221/222 are promising targets for innovative anticancer therapy 66
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 65
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 65
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 65
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo 64
miR-221/222 inhibitors for the treatment of multiple myeloma 64
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 64
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 64
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 63
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 63
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 63
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 63
The non-coding RNA landscape of plasma cell dyscrasias 63
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 63
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 62
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 62
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 62
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 62
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 62
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 62
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 62
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 62
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 62
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 62
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) 61
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients 61
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 61
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 61
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 61
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 61
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 61
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 61
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 60
Totale 7.955
Salva come PNG Salva come JPEG
Categoria #
all - tutte 200.051
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 200.051
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022942 0 0 0 286 57 19 31 202 96 92 146 13
2022/20232.607 722 77 85 210 279 230 13 167 395 162 217 50
2023/20241.366 311 135 116 94 98 321 41 53 15 48 61 73
2024/20254.168 563 250 184 127 234 521 108 155 486 267 423 850
2025/20268.457 412 897 819 1.510 850 326 1.174 486 1.003 566 275 139
2026/20271.957 102 458 916 481 0 0 0 0 0 0 0 0
Totale 20.204